A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Conditions
Recurrent Childhood Acute Myeloid Leukemia · Recurrent Childhood Myelodysplastic Syndrome · Recurrent Juvenile Myelomonocytic Leukemia · Refractory Childhood Acute Myeloid Leukemia · Refractory Childhood Myelodysplastic Syndrome · Refractory Juvenile Myelomonocytic Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Children's Hospital of Alabama, Birmingham, Alabama, United States
Contact: Principal Investigator (Girish Dhall)Children's Hospital of Orange County, Orange, California, United States
Contact: Principal Investigator (Josephine H. Haduong)UCSF Medical Center-Mission Bay, San Francisco, California, United States
Contact: Principal Investigator (Kieuhoa T. Vo)Children's Hospital Colorado, Aurora, Colorado, United States
Contact: Principal Investigator (Margaret E. Macy)Children's National Medical Center, Washington D.C., District of Columbia, United States
Contact: Study coordinator (Site Public Contact) · OncCRC_OnCall@childrensnational.org · 202-476-2800Contact: Principal Investigator (AeRang Kim)Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Contact: Principal Investigator (Jason R. Fangusaro)Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
Contact: Principal Investigator (Sara Zarnegar-Lumley)Riley Hospital for Children, Indianapolis, Indiana, United States
Contact: Principal Investigator (Brian D. Weiss)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Jonathan Paolino)C S Mott Children's Hospital, Ann Arbor, Michigan, United States
Contact: Principal Investigator (Rajen Mody)University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Contact: Principal Investigator (Robin L. Williams)Washington University School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Shalini Shenoy)NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@cumc.columbia.edu · 212-342-5162Contact: Principal Investigator (Nobuko Hijiya)Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Contact: Principal Investigator (Joseph G. Pressey)Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Sarah K. Tasian)Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (Andrew Bukowinski)Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
Contact: Principal Investigator (Matthew Rees)Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Alexandra M. Stevens)Seattle Children's Hospital, Seattle, Washington, United States
Contact: Principal Investigator (Katherine G. Tarlock)
Study leads
Alexandra M Stevens
Principal Investigator
Pediatric Early Phase Clinical Trial Network